SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001600620-24-000049
Filing Date
2024-05-02
Accepted
2024-05-02 06:03:15
Documents
15
Period of Report
2024-05-02
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K auph-20240502.htm   iXBRL 8-K 29076
2 EX-99.1 exhibit991_q12024pressrele.htm EX-99.1 162182
6 aurinalogoa.jpg GRAPHIC 11010
  Complete submission text file 0001600620-24-000049.txt   343586

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20240502.xsd EX-101.SCH 1932
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20240502_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20240502_pre.xml EX-101.PRE 12532
18 EXTRACTED XBRL INSTANCE DOCUMENT auph-20240502_htm.xml XML 2720
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 981231763 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 24905044
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)